JEN BAZS

Please type a plus sign (+) inside this box →

Typed or printed name

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<i></i>	der the Paperwork Reduction Act of 1995, no	persons are required	to respond to a collection of info	ormation unless it displays a valid OMB control number.					
A DE			Application Number	09/593,828					
	TDANIOMITTAL		Filing Date	June 13, 2000					
	TRANSMITTAL	-	First Named Inventor	ROSEN, STEVEN					
	FORM		Group Art Unit	1652					
	(to be used for all correspondence after ini	tial filing)	Examiner Name	MONSHIPOURI, MARYAM					
	Total Number of Dance in This Cubmissis		Attorney Docket Number	UCAL-138					
Total Number of Pages in This Submission ENCLOSURES (check all that apply)									
	Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Documents Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Assign (for an Drawir Licens Petitio Petitio Provis Power Chang Addres Termir Reque	nment Papers Application) ng(s) ing-related Papers n n to Convert to a ional Application of Attorney, Revocation le of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1) Petition to Expunge Information (1 pg.) Information Disclosure Statement (2 pgs.) 3) PTO/SB/08A (1 pg.) 4) Return Postcard					
	SIGNA	TURE OF APPL	ICANT, ATTORNEY, OF	RAGENT					
Signing Attorney/Agent (Reg. No.) PAULA A. BORDEN: 42,344 BOZICEVIC, FIELD & FRANCIS LLP Signature Date June 8, 2004									
	<u> </u>								
			E OF HAND DELIVERY						
I hereby certify that this correspondence is being deposited via hand delivery to U.S. Patent and Trademark Office									

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

...

Date

06-10-2004


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03) Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trauemaix Office, U.S. P U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Complete if Known ÉE TRANSMITTAL 09/593,828 Application Number Filing Date June 13, 2000 for FY 2004 First Named Inventor ROSEN, STEVEN Examiner Name MONSHIPOURI, MARYAM Effective 10/01/2003. Patent fees are subject to annual revision. 1652 Art Unit Applicant claims small entity status. See 37 CFR 1.27 Attorney Docket No. **UCAL-138** TOTAL AMOUNT OF PAYMENT (\$) 130.00 METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) ☐ Check ☐ Credit Card ☐ Other ☐ Money 3. ADDITIONAL FEES Order Deposit Account: Deposit Account 50-0815 arge Entity Small Entity Number Fee Paid Fee Deposit ee Fee Fee Code (\$) Code (\$) Fee Description Account Bozicevic, Field & Francis LLP 1051 130 2051 65 Surcharge - late filing fee or oath Name The Director is authorized to: (check all that apply) 1052 50 2052 25 Surcharge - late provisional filing fee or ☑ Charge fee(s) indicated below ☑ Credit any overpayments cover sheet 1053 1053 130 130 Non-English specification Charge fee(s) indicated below, except for the filing fee 1812 1812 2,520 For filing a request for ex parte reexamination 2.520 to the above-identified deposit account. 1804 1804 9201 Requesting publication of SIR prior to **FEE CALCULATION** Examination action 1805 1,8401 1805 1.840*Requesting publication of SIR after **BASIC FILING FEE** Examiner action **Entity Small Entity** Large 1251 Fee **Eee Description** 110 2251 Extension for reply within first month Fee Fee Fee Fee Paid Code (\$) Code (\$) 1252 2252 420 210 Extension for reply within second month 1001 770 2001 385 Utility filing fee 1253 950 2253 475 Extension for reply within third month 1002 340 2002 170 Design filing fee 1254 1,480 2254 Extension for reply within fourth month 1003 530 2003 265 Plant filing fee 1255 2,010 2255 1,005 Extension for reply within fifth month 1004 770 2004 385 Reissue filing fee 1401 330 2401 165 Notice of Appeal 1005 160 2005 80 Provisional filing fee 1402 330 2402 165 Filing a brief in support of an appeal 1403 290 2403 Request for oral hearing SUBTOTAL (1) 1451 1,510 1451 1,510 Petition to institute a public use proceeding 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1452 110 2452 55 Petition to revive - unavoidable Fee from Extra Claims below Fee Paid 1453 1,330 2453 665 Petition to revive - unintentional 1501 1,330 2501 665 Utility issue fee (or reissue) Total Claims -20** = 1502 480 2502 240 Design issue fee Indep. -3** = Claims 1503 2503 640 320 Plant issue fee 130.00 Multiple Dependent 1406 130 1460 130 Petitions to the Commissioner Large Entity | Small Entity 1807 1807 50 50 Processing fee under 37 CFR 1.17(q) Fee Description 808 1806 180 180 Submission of Information Disclosure Stmt Code (\$) Code (\$) 1202 8021 18 2202 9 Claims in excess of 20 40 8021 40 Recording each patent assignment per property (times number of properties) 1201 86 2201 43 Independent claims in excess of 3 2809 1809 770 385 Filing a submission after final rejection 1203 290 2203 145 Multiple dependent claim, if not paid (37 CFR § 1.129(a)) 1204 ** Reissue independent claims 86 2204 43 1810 770 2810 385 For each additional invention to be over original patent examined (37 CFR § 1.129(b)) 1205 18 2205 Reissue claims in excess of 20 and over original patent 1801 770 2801 385 Request for Continued Examination (RCE) SUBTOTAL (2) \$ 0.00 1802 900 1802 Request for expedited examination of a design application or number previously paid, if greater, For Reissues, see above, Other fee (specify) 130.00 *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)

SUBMITTED BY			Complete	(if applicable)	•	
Name (Print/Type)	Paula A. Borden	Registration No. (Attorney/Agent)	42,344	Telephone	(650) 833-7710	
Signature	(and	\nearrow		Date	06/08/2004	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



This is a Petition under 37 C.F.R.§1.59(b), which Petition is being filed concurrently with an Information Disclosure Statement (IDS) and PTO form SB/08A. As provided for under 37 C.F.R.§1.59(b), Applicants respectfully request that the Office expunge and return the information that is indicated as proprietary and that is included in the IDS being filed herewith.

The accompanying IDS contains information that is proprietary. The proprietary information was separately hand delivered to Technology Center 1600. The proprietary information in the accompanying IDS has been labeled as such. To the best of our knowledge, the proprietary material has not been made public. The proprietary information will be retained by the petitioner for the period of any patent with regard to which the information is submitted. This Petition to Expunge is being submitted on behalf of the party who originally submitted the proprietary information.

The \$130.00 fee set forth in 37 C.F.R. §1.17(h) to cover the petition accompanies this Petition. The Commissioner is hereby authorized to charge fees associated with the filing of this petition, and any additional fees which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Date: June 8, 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\UCAL\138\petition under 1.59b.doc

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Paula A. Borden


Registration No. 42,344

130.00 DA

06/15/2004 ИАНЖЕD1 00000075 500В15

09593828

FC:1460 1



Sir:

This is an Information Disclosure Statement (IDS) submitted for the Examiner's consideration. This IDS is being filed concurrently with a Request for Continued Examination.

A Form SB08A listing the references accompanies this paper. Applicants would appreciate the Examiner initialing and returning the form to indicate that the references have been reviewed and made of record.

Incyte Lifeseq clone numbers 1846903; 3219891; 3372492; 3373406: 3126392; 6869651; and GenBank accession numbers AA 261202; AI 282873; AC 009105; AC 009163; AC 011934; AC 025287; AC 026419; and AF 176838 were disclosed under Example 1, Cloning of GST-4, beginning at page 41 of the instant specification. Incyte Lifeseq clone number 0182182 and GenBank accession numbers AI 528511 and AC 010547 were disclosed under Example 2, Cloning of GST-6, beginning at page 45 of the instant specification.

Pursuant to M.P.E.P. section 724.02, Applicants submit concurrently (via hand delivery to Technology Center 1600) in an envelope marked as proprietary that contains the nucleic acid sequence for the following:

Incyte Lifeseq clone no.3373406;

Incyte Lifeseq clone no.3372492;

Incyte Lifeseq clone no.3126392;

Incyte Lifeseq clone no.3219891;

Incyte Lifeseq clone no.1846903;

Incyte Lifeseq clone no.6869651; and

Incyte Lifeseg clone no.0182182.

Atty Dkt. No.: UCAL138

USSN: 09/593,828

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

No fee is believed to be required with the filing of the Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, the Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 50-0815, Order No. UCAL-138.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

June 8, 2004

Paula A. Borden, Reg. No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650)327-3231

F:\DOCUMENT\UCAL\138\ids proprietary.doc

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

JUN 1 0 2004 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

09/593,828 **Application Number** June 13, 2000 Filing Date First Named Inventor **ROSEN** Group Art Unit 1652 MONSHIPOURI, MARYAM **Examiner Name**

(use as many sheets as necessary)

Sheet 1 Attorney Docket Number **UCAL-138**

				U.S. PATENT DOCUM	MENTS	
Examin er Initials'	Cite No. ¹	U.S. Pat Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
	-					

FOREIGN PATENT DOCUMENTS									
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		ocuments	Name of Patentee or	Date of Publication	Pages, Columns, Lines,		
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Incyte Lifeseg clone no.3373406					
		Incyte Lifeseq clone no.3372492					
		Incyte Lifeseg clone no.3126392					
		Incyte Lifeseg clone no.3219891					
		Incyte Lifeseg clone no.1846903					
		Incyte Lifeseg clone no.6869651					
		Incyte Lifeseg clone no.0182182					

F"		
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.